An increasing number of high cost therapies are being approved for patient use, and these often interact with employers’ stop-loss coverage due to their high prices. While the stop-loss industry has historically relied on traditional underwriting methods such as reducing coverage for high-risk patients, other methods of financing high cost drugs are being explored. What does the current stop-loss landscape look like?

This article was commissioned by Genentech, Inc.